The Zhitong Finance App learned that Citi published a research report to maintain Moderna (MRNA.US) “sell” rating and a target price of $80. The bank pointed out that Moderna's investor conference call during the European Society of Medical Oncology (ESMO) further strengthened management's confidence in individualized oncology treatment platforms, but did not substantially change Citi's views on the limitations of commercialization and the disconnect in valuation.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.